Cellectis S.a Stock News

NEW YORK, March 11, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to

French clinical-stage biotechnological company, Cellectis <> is trading higher for the fourth consecutive session on Friday as the market reacts to the Fast Track designation…

Clearside Biomedical CLSD +38%. Cellectis (CLLS) +13%. Orphazyme ORPH -37%. Aesthetic Medical International (AIH) -19%.

NEW YORK , March 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EXN, CLLS, SDPI, SFET, and DS. … Full story available on Benzinga.com

Investors saw a bargain when the stock hit its 52-week low early in the week.

Investors saw a bargain when the stock hit its 52-week low early in the week.

Cellectis S.A. (CLLS) CEO Andre Choulika on Q4 2021 Results - Earnings Call Transcript

NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop potentially life-saving cell and gene therapies, announced its results for the fourth quarter of 2021, and full year ending December 31, 2021.

Cellectis press release (CLLS): Q4 GAAP EPS of -$0.18.Revenue of $1.94M (-86.0% Y/Y).The company said the decrease was driven by lower volumes of product sold in 2021 as it…

Cellectis (NASDAQ:CLLS) is scheduled to announce Q4 earnings results on Thursday, March 3rd, after market close.The consensus EPS Estimate is -$0.88 (-166.7% Y/Y) and the consensus…

Cellectis S.A. (NASDAQ:CLLS) concluded the trading at $4.40 on Friday, February 25 with a rise of 2.56% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $4.29 and 5Y monthly beta was reading 2.19 with its price kept floating in the range … Cellectis S.A.’S 2.56% Escalation Justifies Another Look Read More »

Cellectis (CLLS) appointed Bing Wang as CFO and member of its executive committee.Prior to joining CLLS, Wang was most recently CEO of Refuge Biotechnologies

NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced the appointment of Bing C. Wang, PhD, MBA, as Chief Financial Officer and member of Cellectis’ executive committee.

Arovella Therapeutics Ltd (ASX:ALA) has welcomed Dr Mini Bharathan to the executive team to lead preclinical trials of the newly acquired DKK1 peptide targeting technology and its CAR19-iNKT cell the

(RTTNews) - Cellectis said its licensed partner, Allogene Therapeutics Inc. (ALLO) announced that the U.S. Food and Drug Administration has lifted the clinical hold on its cancer drug trial. Allogene reported that the FDA''s investigations concluded that the chromosomal abnormality was unrelated to TALEN gene editing or Allogene''s manufacturing